{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chlamydia-uncomplicated-genital/prescribing-information/doxycycline/","result":{"pageContext":{"chapter":{"id":"f100927d-5a5a-5112-bec9-59e5e4d4f040","slug":"doxycycline","fullItemName":"Doxycycline","depth":2,"htmlHeader":"<!-- begin field dbbb43e5-3a49-49ba-bcbf-0f1aa4450764 --><h2>Doxycycline</h2><!-- end field dbbb43e5-3a49-49ba-bcbf-0f1aa4450764 -->","summary":"","htmlStringContent":"<!-- begin item dcaccbf8-ff6b-4e3c-a864-7971f5951281 --><!-- end item dcaccbf8-ff6b-4e3c-a864-7971f5951281 -->","topic":{"id":"9fd72b23-86c9-5ce5-bbdd-598398d0e8ea","topicId":"7ce33f6f-747f-41e5-b18b-09b2071a7d93","topicName":"Chlamydia - uncomplicated genital","slug":"chlamydia-uncomplicated-genital","lastRevised":"Last revised in January 2021","chapters":[{"id":"0b0636d2-117b-5108-b70c-d19a794db377","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"dda664e4-4864-5386-8bf2-ae38fe324071","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6af905a1-8c41-53d9-b5ca-e96a0b2548be","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"84014645-1e22-51ca-b89b-52cd820d41b7","slug":"changes","fullItemName":"Changes"},{"id":"66fb5a16-c4f5-562e-9a73-84371e2bbe0d","slug":"update","fullItemName":"Update"}]},{"id":"82517c94-8e8a-5c62-b7d6-670ad4404258","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"0f150da5-1397-5e5d-b3dd-c9f2716423aa","slug":"goals","fullItemName":"Goals"},{"id":"f52e0aef-b3ad-5e13-b9ed-d426b4fa2f77","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ba38cbe0-ef08-5c56-a1f4-9a962b32ad9f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2ced83fa-49d9-5243-8a7f-d942baa4bc1f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"5887995c-3455-537d-98cc-b1aeb54144ed","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0f2bffb-9529-57db-a995-191cba2d4e9f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"824044f0-a305-5a18-9a1d-bf36875a6ce8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5b8da5a2-6086-58db-9ad4-94fe2eb8bd48","slug":"definition","fullItemName":"Definition"},{"id":"ae31b546-618f-5b61-bf90-254c4868b504","slug":"prevalence","fullItemName":"Prevalence"},{"id":"8cd27f8c-d2f1-57ac-83e8-ed035b78ee51","slug":"risk-factors","fullItemName":"Risk Factors"},{"id":"ab8dc958-d4dc-5fef-ac7c-bc2b5865fdbe","slug":"prognosis-complications","fullItemName":"Prognosis and complications"}]},{"id":"3a69be68-2fd6-509b-85f4-164afc701ba8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a927a8de-387f-5d99-8924-b8836a37e1a0","slug":"screening-for-chlamydia-in-asymptomatic-men-women","fullItemName":"Screening for chlamydia in asymptomatic men and women"},{"id":"9da777e0-887a-5bb6-af7a-f6f0b986dbf4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"0a0b5d7a-0455-5688-90d5-253f427816b6","slug":"testing-to-confirm-the-diagnosis","fullItemName":"Testing to confirm the diagnosis"}]},{"id":"366e3be0-ac7e-5c90-baed-b3485d6e47ae","fullItemName":"Management","slug":"management","subChapters":[{"id":"9b3c090d-c63e-54c5-8cd1-1f401bc12c7b","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"e1354798-4643-56ab-8360-3c7075ebaa79","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"0cd2f484-1947-55ec-980e-1d0293ab355e","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"48da76f5-5041-504f-ab81-69b4fe7ff549","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"f100927d-5a5a-5112-bec9-59e5e4d4f040","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"07eef3f6-7862-5fc9-b60f-ffa9d201996a","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"dacb6886-00ac-5160-9ee9-3ec19959d6ee","slug":"ofloxacin","fullItemName":"Ofloxacin"}]},{"id":"41a663fd-74e7-5b4b-b936-d4894268ff1f","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"34dd7d77-0b55-5661-b769-73e6cade3309","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ffbef724-e30a-592a-836b-c4c5163d2e15","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0964fb39-dd03-54bb-af48-c376a46d685b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d69f8f7d-515f-5861-85b0-f5d6cf0ecfac","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2c32cb59-e5a3-5af2-b976-e11d73a2ea8a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"87f9e401-f03f-547f-a524-e2f66bfb58c0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"69fd8a3f-633f-5092-85dd-f2220728872d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e1354798-4643-56ab-8360-3c7075ebaa79","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"9a9b08e7-3f69-54fa-ba23-3d56e6cc0161","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 46aa9fb7-4519-419a-81c6-d7bd1e079ff1 --><h3>What contraindications and cautions are important with doxycycline?</h3><!-- end field 46aa9fb7-4519-419a-81c6-d7bd1e079ff1 -->","summary":"","htmlStringContent":"<!-- begin item 555bdc43-2aef-4790-b0f6-7b7f0f8243bb --><!-- begin field a84a8430-9cf7-41d2-9613-7fc704c1a4bc --><p><strong>Do not prescribe doxycycline to:</strong></p><ul><li>Pregnant or breastfeeding women.</li><li>People with:<ul><li>Liver disease.</li><li>Systemic lupus erythematosus.</li><li>Myasthenia gravis.</li><li>Porphyria.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">ABPI Medicines Compendium, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">BNF 71, 2016</a>]</p><!-- end field a84a8430-9cf7-41d2-9613-7fc704c1a4bc --><!-- end item 555bdc43-2aef-4790-b0f6-7b7f0f8243bb -->","subChapters":[]},{"id":"4d241aca-0a88-56ef-9e81-bf4598e3424d","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 788b64a4-d434-4e3a-967e-518394bdec94 --><h3>What are the adverse effects of doxycycline?</h3><!-- end field 788b64a4-d434-4e3a-967e-518394bdec94 -->","summary":"","htmlStringContent":"<!-- begin item 1eb66220-0ae0-4f5c-8eea-a8ef6e636275 --><!-- begin field 99de3f00-8d16-4219-8b9d-f8bf05da128b --><p><strong>The adverse effects of doxycycline include:</strong></p><ul><li>Gastrointestinal adverse effects, such as nausea, vomiting, and diarrhoea.</li><li>Less frequently, doxycycline may cause photosensitivity.<ul><li>Advise the person to minimize exposure to direct sunlight.</li></ul></li><li>Severe adverse effects are unusual with a short course. However, benign intracranial hypertension has rarely been reported following treatment with a tetracycline.<ul><li>If a person taking doxycyline develops headache and visual disturbance, the drug should be stopped immediately.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">ABPI Medicines Compendium, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">BNF 71, 2016</a>]</p><!-- end field 99de3f00-8d16-4219-8b9d-f8bf05da128b --><!-- end item 1eb66220-0ae0-4f5c-8eea-a8ef6e636275 -->","subChapters":[]},{"id":"1411265a-2f06-53ae-966f-91484c7a2125","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field e243b7e6-bd98-439f-a762-3dcbdc680a9d --><h3>What drug interactions are important with doxycycline?</h3><!-- end field e243b7e6-bd98-439f-a762-3dcbdc680a9d -->","summary":"","htmlStringContent":"<!-- begin item 8faa0afa-e093-403d-a77f-61663bf76570 --><!-- begin field 0d491ca3-704a-4fca-8831-aba7c50b4cd1 --><ul><li><strong>Phenobarbital, carbamazepine, phenytoin, and primidone</strong> — metabolism of doxycycline may be accelerated by these drugs, leading to a reduced plasma concentration.<ul><li>Monitor the therapeutic effect of doxycyline, as a dose increase may be necessary.</li></ul></li><li><strong>Rifampicin </strong>— may cause a reduction in doxycycline levels, leading to undertreatment.<ul><li>Monitor the effects of concurrent use and increase the doxycycline dosage as necessary.</li></ul></li><li><strong>Sucralfate and antacids </strong>— can reduce the absorption of tetracyclines.<ul><li>Advise the person taking a tetracycline to wait at least 2 hours before taking sucralfate or antacids.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">ABPI Medicines Compendium, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">Preston, 2015</a>]</p><!-- end field 0d491ca3-704a-4fca-8831-aba7c50b4cd1 --><!-- end item 8faa0afa-e093-403d-a77f-61663bf76570 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}